Current status and future directions of immunotherapy for advanced non-small cell lung cancer

Abstract

Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Immune checkpoint inhibitors (ICIs)-based therapy targeting programmed death protein-1 (PD-1) or its ligand programmed death ligand-1 (PD-L1) has become one of the standard treatments for advanced NSCLC. This review, with the focus on advanced NSCLC, summarized the development of immunotherapy, discussed current problems, and challenges and proposed future directions.

Keywords

• |non-small cell lung cancer|immune checkpoint inhibitor|immunotherapy